Department of Endocrinology, Beijing University of Chinese Medicine East Hospital, Qinhuangdao Hospital of Traditional Chinese Medicine, Qinhuangdao, China.
Department Four of Recuperation, Second Sanatorium of Qingdao Special Recuperation Center of PLA Navy, Qingdao, China.
Endocrinol Diabetes Nutr (Engl Ed). 2024 Nov;71(9):372-379. doi: 10.1016/j.endien.2024.11.002.
To investigate the serum levels of miR-409-3p in patients with type 2 diabetes mellitus (T2DM) complicated with coronary heart disease (CHD) and its effect on high glucose (HG)-induced myocardial cell injury.
A total of 250 patients with T2DM admitted to our hospital from April 2020 through April 2022 were enrolled as the study subjects, and then grouped into T2DM+CHD (group #1) and T2DM (group #2). Real-time quantitative PCR (RT-qPCR) was used to measure the levels of serum miR-409-3p. The clinical performance of miR-409-3p was evaluated. The human cardiomyocyte AC16 cells were cultured in vitro and treated with HG. MTT assay and flow cytometry were performed to detect cell viability and apoptosis, respectively. Bioinformatic analyses were performed to explore the potential mechanism of miR-409-3p in T2DM complicated with CHD.
The expression level of miR-409-3p was increased in the T2DM+CHD group and had a relative high diagnostic value for distinguishing patients with T2DM+CHD from patients with T2DM alone. Correlation analysis showed that serum miR-409-3p was positively associated with the Gensini score and adverse cardiovascular events; miR-409-3p knockdown alleviated HG-induced AC16 cell damage and reduced cell apoptosis. CREB1, BCL2, and SMAD2 were the top 3 hub genes of miR-409-3p.
Serum miR-409-3p may serve as a potential diagnostic and prognostic biomarker for predicting T2DM complicated with CHD and forecast adverse events. Targeting miR-409-3p may be a novel therapeutic strategy to intervene in the development of T2DM+CHD.
探讨 2 型糖尿病（T2DM）合并冠心病（CHD）患者血清 miR-409-3p 水平及其对高糖（HG）诱导心肌细胞损伤的影响。
选取 2020 年 4 月至 2022 年 4 月我院收治的 250 例 T2DM 患者为研究对象，根据是否合并 CHD 分为 T2DM+CHD 组（#1 组）和 T2DM 组（#2 组）。采用实时定量 PCR（RT-qPCR）检测血清 miR-409-3p 水平，评估 miR-409-3p 的临床性能。体外培养人心肌细胞 AC16 并给予 HG 处理，MTT 法和流式细胞术分别检测细胞活力和凋亡。通过生物信息学分析探讨 miR-409-3p 在 T2DM 合并 CHD 中的潜在作用机制。
T2DM+CHD 组 miR-409-3p 表达水平升高，对鉴别 T2DM 合并 CHD 患者和单纯 T2DM 患者具有较高的诊断价值。相关性分析显示，血清 miR-409-3p 与 Gensini 评分及不良心血管事件呈正相关；miR-409-3p 敲低可减轻 HG 诱导的 AC16 细胞损伤，减少细胞凋亡。CREB1、BCL2 和 SMAD2 是 miR-409-3p 的前 3 个核心基因。
血清 miR-409-3p 可能是预测 T2DM 合并 CHD 及不良事件的潜在诊断和预后生物标志物。靶向 miR-409-3p 可能是干预 T2DM+CHD 发展的新治疗策略。
